-
A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma. Oncologist (IF 5.8) Pub Date : 2023-11-30 Marco Maria Germani,Chiara Boccaccio,Antonio Matrone,Eleonora Molinaro,Greta Alì,Mirella Giordano,Rossella Elisei,Gabriella Fontanini,Chiara Cremolini
Herein, we present a misleading case of advanced papillary thyroid carcinoma with lung, node, and pleural metastases, initially diagnosed as metastatic lung adenocarcinoma with papillary features, based on the histological and immunohistochemical analysis of a pleural biopsy. Between August 2019 and August 2020, the patient received 2 ineffective lines of systemic therapy, including a first line of
-
Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist (IF 5.8) Pub Date : 2023-11-30 Andrew W Hahn,Devaki Shilpa Surasi,Paul V Viscuse,Tharakeswara K Bathala,Andrew J Wiele,Matthew T Campbell,Amado J Zurita,Amishi Y Shah,Eric Jonasch,Jianjun Gao,Sangeeta Goswami,Omar Alhalabi,Priya Rao,Kanishka Sircar,Nizar M Tannir,Pavlos Msaouel
BACKGROUND Metastatic RCC with sarcomatoid and/or rhabdoid (S/R) dedifferentiation is an aggressive disease associated with improved response to immune checkpoint therapy (ICT). The outcomes of patients treated with VEGFR-targeted therapies (TT) following ICT progression have not been investigated. PATIENTS AND METHODS Retrospective review of 57 patients with sarcomatoid (S), rhabdoid (R), or sarcomatoid
-
-
Trajectory of Healthcare Contact Days for Veterans With Advanced Gastrointestinal Malignancy. Oncologist (IF 5.8) Pub Date : 2023-11-28 Whitney V Johnson,Quan H Phung,Vishal R Patel,Alexander K Tsai,Nivedita Arora,Mark A Klein,Anders D Westanmo,Anne H Blaes,Arjun Gupta
How and where patients with advanced cancer facing limited survival spend their time is critical. Healthcare contact days (days with healthcare contact outside the home) offer a patient-centered and practical measure of how much of a person's life is consumed by healthcare. We retrospectively analyzed contact days among decedent veterans with stage IV gastrointestinal cancer at the Minneapolis Veterans
-
Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast Cancer. Oncologist (IF 5.8) Pub Date : 2023-11-25 Edurne Arriola,Jana Jaal,Anne Edvardsen,Maria Silvoniemi,António Araújo,Anders Vikström,Eleni Zairi,Mari Carmen Rodriguez-Mues,Marco Roccato,Sophie Schneider,Johannes Ammann
BACKGROUND Digital patient monitoring (DPM) tools can facilitate early symptom management for patients with cancer through systematic symptom reporting; however, low adherence can be a challenge. We assessed patient/healthcare professional (HCP) use of DPM in routine clinical practice. MATERIALS AND METHODS Patients with locally advanced/metastatic lung cancer or HER2-positive breast cancer received
-
Patient Priorities Concerning Treatment Decisions for Advanced Neuroendocrine Tumors Identified by Discrete Choice Experiments. Oncologist (IF 5.8) Pub Date : 2023-11-25 Matthew Anaka,David Chan,Sharon Pattison,Alia Thawer,Bryan Franco,Lesley Moody,Christopher Jackson,Eva Segelov,Simron Singh
BACKGROUND Patients with advanced neuroendocrine tumors (NETs) have multiple treatment options. Ideally, treatment decisions are shared between physician and patient; however, previous studies suggest that oncologists and patients place different value on treatment attributes such as adverse event (AE) rates. High-quality information on NET patient treatment preferences may facilitate patient-centered
-
Treatment of Hypercalcemic Hyperparathyroidism After Kidney Transplantation Is Associated With Improved Allograft Survival. Oncologist (IF 5.8) Pub Date : 2023-11-24 Rongzhi Wang,Rhiannon D Reed,Griffin Price,Peter Abraham,Marshall Lewis,Jessica Liu McMullin,Paul MacLennan,Cozette Killian,Jayme E Locke,Song Ong,Vineeta Kumar,Andrea Gillis,Brenessa Lindeman,Herbert Chen,Jessica Fazendin
BACKGROUND Hyperparathyroidism (HPT) and malignancy are the most common causes of hypercalcemia. Among kidney transplant (KT) recipients, hypercalcemia is mostly caused by tertiary HPT. Persistent tertiary HPT after KT is associated with allograft failure. Previous studies on managing tHPT were subjected to survivor treatment selection bias; as such, the impact of tertiary HPT treatment on allograft
-
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study. Oncologist (IF 5.8) Pub Date : 2023-11-23 Andrea Botticelli,Roberta Caputo,Simone Scagnoli,Simona Pisegna,Michelino De Laurentiis,Giuseppe Curigliano,Matteo Lambertini,Francesco Pantano,Antonella Palazzo,Ida Paris,Claudio Vernieri,Beatrice Tedesco,Marianna Giampaglia,Michela Palleschi,Zelmira Ballatore,Daniele Alesini,Giuliana D'Auria,Agnese Fabbri,Luigi Rossi,Annarita Verrazzo,Roberta Scafetta,Daniele Marinelli,Caterina Sposetti,Vittoria
BACKGROUND Trastuzumab deruxtecan (T-DXd) demonstrated unprecedented efficacy in patients with pretreated HER2+ metastatic breast cancer (mBC). However, few data are available about its efficacy in routine clinical practice. In this multicenter retrospective study, we examined effectiveness and safety of T-DXd in a real-world population. METHODS Clinico-pathological information about patients with
-
Prognostic Role of p53 Immunohistochemical Status in invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors. Oncologist (IF 5.8) Pub Date : 2023-11-23 Gerti Dajti,Margherita Serra,Giovanni Cisternino,Claudio Ceccarelli,Alice Pellegrini,Marica Melina,Antonio De Leo,Donatella Santini,Mario Taffurelli,Simone Zanotti
PURPOSE The aim of this study was to evaluate the prognostic role of p53 immunohistochemical (IHC) expression in a large cohort of patients with hormone receptors (HR)-positive/Her2-negative primary invasive breast cancer. METHODS Retrospective review of consecutive cases treated at our Breast Unit between 2003 and 2013. Patients were divided into 3 subgroups based on p53 IHC expression: null (0%)
-
Patient-Reported Outcomes of Accelerated Aging: A Novel Approach to Investigate Second Cancer Risk in Adolescent and Young Adult (18-39 Years) Cancer Survivors. Oncologist (IF 5.8) Pub Date : 2023-11-23 Daniël J van der Meer,Susan Zevenbergen,Carla Vlooswijk,Rhodé M Bijlsma,Suzanne E J Kaal,Jan Martijn Kerst,Jacqueline M Tromp,Monique E M M Bos,Tom van der Hulle,Roy I Lalisang,Janine Nuver,Mathilde C M Kouwenhoven,Winette T A van der Graaf,Olga Husson
BACKGROUND Adolescent and young adult cancer survivors (AYAs, aged 18-39 years at first diagnosis) have a higher second cancer risk. Accelerated aging is hypothesized as underlying mechanism and has been described clinically by 6 indicators; fatigue, low quality of sleep, low mood, lack of motivation, subjective memory complaints, and poor exercise tolerance. Using patient-reported outcomes, we aimed
-
Head and Neck Squamous Cell Carcinoma of Unknown Primary: A Diagnostic Work-Up. Oncologist (IF 5.8) Pub Date : 2023-11-23 Meenakkshy Manoharan,Noah S Kalman,Guilherme Rabinowits
The current work-up of the primary tumor site of a head and neck squamous cell carcinoma of unknown primary is not standardized and results in several time-consuming procedures that delay treatment initiation. This article seeks to consolidate contemporary strategies used to identify the primary tumor site of an unknown primary head and neck squamous cell carcinoma and offer recommendations based on
-
Perspectives on the Treatment of Multiple Myeloma. Oncologist (IF 5.8) Pub Date : 2023-11-23 Abdul Rafae,Frits van Rhee,Samer Al Hadidi
The treatment of multiple myeloma has evolved significantly over the past few decades with the development of novel therapeutics. The introduction of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and high-dose chemotherapy followed by hematopoietic stem cell transplantation has led to improved response rates and survival outcomes. The use of bispecific antibodies and chimeric
-
Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review. Oncologist (IF 5.8) Pub Date : 2023-11-23 Charlotte Sikking,Kelly L Niggebrugge-Mentink,A S Elise van der Sman,Roefke H P Smit,Esther W Bouman-Wammes,Marieke M Beex-Oosterhuis,Charlotte van Kesteren
INTRODUCTION Cisplatin-induced nephrotoxicity (CIN) can be prevented by fluid hydration, electrolyte supplementation, or forced diuresis; however, the best way to prevent CIN is still unknown. The aim of this study was to provide objective evidence on the optimal design of hydration schemes to prevent CIN based on an update of the literature. METHODS A Pubmed and Embase search were conducted in December
-
Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients. Oncologist (IF 5.8) Pub Date : 2023-11-23 Jiun-I Lai,Ting-Hao Kuo,Kuan-Jung Huang,Laura Min Xuan Chai,Mei-Hsuan Lee,Chun-Yu Liu,Yi-Fang Tsai,Chi-Cheng Huang,Ling-Ming Tseng,Cheng-Chih Hsu,Ta-Chung Chao
BACKGROUND CDK4/6 inhibitors (CDK4/6i) have shown great efficacy in prolonging progression-free survival and is the current standard of care for hormone positive (HR(+)) metastatic breast cancer (mBC). Despite well tolerability and ease of use, the most common side effect of CDK4/6i is myelosuppression, with neutropenia the most prevalent adverse effect. Studies show that the prevalence and severity
-
Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial. Oncologist (IF 5.8) Pub Date : 2023-11-16 Eriko Tokunaga,Yasuo Miyoshi,Koji Dozono,Tsutomu Kawaguchi,Masakazu Toi
BACKGROUND Established prognostic factors for treatment response to cyclin-dependent kinases 4 and 6 inhibitors are currently lacking. We aimed to investigate the relationship of pretreatment neutrophil-to-lymphocyte ratio (NLR) and absolute lymphocyte count (ALC) to abemaciclib outcomes. PATIENTS AND METHODS This was a post hoc analysis of data from MONARCH 2, a phase III study of abemaciclib or placebo
-
Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors. Oncologist (IF 5.8) Pub Date : 2023-11-16 Adriana M Kahn,Curtis J Perry,Katrina Etts,Harriet Kluger,Mario Sznol
Prospective and between trial comparisons indicate that first-line treatment with immune checkpoint inhibitors improves survival outcomes compared to first-line therapy with combined BRAF and MEK inhibitors in metastatic melanoma containing BRAFV600E/K mutations. Long-term outcomes for BRAF/MEK inhibition after progression on immunotherapy have not been reported. Moreover, clinical variables associated
-
Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics. Oncologist (IF 5.8) Pub Date : 2023-11-16 Sara Socorro Faria,Diana Giannarelli,Vladmir Claudio Cordeiro de Lima,Sumadi Luckman Anwar,Chiara Casadei,Ugo De Giorgi,Gabriele Madonna,Paolo Antonio Ascierto,Rossana Veronica Mendoza López,Roger Chammas,Mariaelena Capone
BACKGROUND Breast cancer-related inflammation is critical in tumorigenesis, cancer progression, and patient prognosis. Several inflammatory markers derived from peripheral blood cells count, such as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), and systemic immune-inflammation index (SII) are considered as prognostic markers in several types
-
The Use of Wearable Devices in Oncology Patients: A Systematic Review. Oncologist (IF 5.8) Pub Date : 2023-11-16 Ronald Chow,Hannah Drkulec,James H B Im,Jane Tsai,Abdulwadud Nafees,Swetlana Kumar,Tristan Hou,Rouhi Fazelzad,Natasha B Leighl,Monika Krzyzanowska,Philip Wong,Srinivas Raman
INTRODUCTION The aim of this systematic review was to summarize the current literature on wearable technologies in oncology patients for the purpose of prognostication, treatment monitoring, and rehabilitation planning. METHODS A search was conducted in Medline ALL, Cochrane Central Register of Controlled Trials, Embase, Emcare, CINAHL, Scopus, and Web of Science, up until February 2022. Articles were
-
Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G). Oncologist (IF 5.8) Pub Date : 2023-11-10 Yosuke Kito,Hisato Kawakami,Seiichiro Mitani,Shinichi Nishina,Toshihiko Matsumoto,Takao Tsuzuki,Yudai Shinohara,Hozumi Shimokawa,Ryosuke Kumanishi,Takashi Ohta,Hiroo Katsuya,Takeshi Kawakami,Tomohiro Nishina,Hiroko Hasegawa,Kohei Akiyoshi,Yasutaka Chiba,Kentaro Yamazaki,Shuichi Hironaka,Kei Muro
BACKGROUND Trifluridine/tipiracil (FTD/TPI) plus bevacizumab has shown clinical benefit for metastatic colorectal cancer (mCRC) refractory to standard therapy. However, few data have been available for patients with pretreated mCRC who are intolerant of intensive therapy (vulnerable). METHODS We performed a multicenter retrospective study (WJOG14520G; TWILIGHT) of FTD/TPI plus bevacizumab for vulnerable
-
A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma. Oncologist (IF 5.8) Pub Date : 2023-11-10 Rana R McKay,Katharina Leucht,Wanling Xie,Opeyemi Jegede,David A Braun,Michael B Atkins,Marc-Oliver Grimm,Toni K Choueiri
BACKGROUND Nivolumab plus ipilimumab has demonstrated improved survival for treatment-naïve advanced clear cell renal cell carcinoma (RCC). A series of clinical trials evaluated the effect of salvage nivolumab plus ipilimumab in patients without an objective response to nivolumab. Given the size and heterogeneity of these studies, we performed a pooled analysis to better inform the activity of nivolumab
-
Opioid and Non-Opioid Pharmacotherapy Use for Pain Management Among Privately Insured Pediatric Patients With Cancer in the United States. Oncologist (IF 5.8) Pub Date : 2023-11-07 Chan Shen,J Douglas Thornton,Ning Li,Eric Schaefer,Shouhao Zhou,Sarah Kawasaki,Colette Pameijer,Douglas Leslie
BACKGROUND This study examined the trends and patterns of opioid and non-opioid pharmacotherapy use among a large national sample of privately insured pediatric patients with cancer in the United States. MATERIALS AND METHODS We identified pediatric (aged < 21) patients diagnosed with central nervous system (CNS), lymphoma, gonadal, leukemia, or bone cancer from MarketScan data 2005-2019. We examined
-
Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial. Oncologist (IF 5.8) Pub Date : 2023-11-03 Lorenzo Gerratana,Masha Kocherginsky,Andrew A Davis,Paolo D'Amico,Carolina Reduzzi,Fabio Puglisi,Massimo Cristofanilli
BACKGROUND The MONARCH 2 trial (NCT02107703) showed the efficacy of abemaciclib, a cyclin-dependent kinase 4 & 6 inhibitor (CDK4/6i), in combination with fulvestrant for hormone receptor-positive, HER2-negative metastatic breast cancer (MBC). The aim of this analysis was to explore the prediction of circulating tumor cells (CTCs) stratification using machine learning for hypothesis generation of biomarker-driven
-
Coping and Perception of Prognosis in Patients With Indolent Non-Hodgkin's Lymphoma. Oncologist (IF 5.8) Pub Date : 2023-11-03 Richard A Newcomb,P Connor Johnson,Daniel Yang,Katherine Holmbeck,Joanna Choe,Anisa Nabily,Porsha Lark,Tejaswini Dhawale,Hermioni L Amonoo,Areej El-Jawahri
BACKGROUND Indolent non-Hodgkin's lymphomas (iNHL) are a heterogenous group of mostly incurable diseases with prolonged illness courses and prognostic uncertainty. Yet, studies evaluating coping and perception of prognosis are limited. METHODS We conducted a cross-sectional study of adults newly diagnosed with iNHL in the past 3 months at a single academic center. We assessed quality of life (QOL:
-
Place of Death for Israeli Cancer Patients Over a 20-Year Period: Reducing Hospital Deaths, but Barriers Remain. Oncologist (IF 5.8) Pub Date : 2023-11-02 Yuval Shalev Many,Pesach Shvartzman,Ido Wolf,Barbara G Silverman
BACKGROUND Cancer remains a leading cause of mortality worldwide. While the main focus of palliative care (PC) is quality of life, the elements that comprise the quality of death are often overlooked. Dying at home, with home-hospice-care (HHC) support, rather than in-hospital, may increase patient satisfaction and decrease the use of invasive measures. We examined clinical and demographic characteristics
-
-
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer. Oncologist (IF 5.8) Pub Date : 2023-11-02 Juan Luis Gomez Marti,Azadeh Nasrazadani,Ying Ding,Daniel Normolle,Adam M Brufsky
BACKGROUND As the implementation of trastuzumab, several studies have investigated new agents and regimens to treat human epidermal growth factor 2-positive (HER2+) metastatic breast cancer (MBC). However, long-term survival analyses from HER2-targeted therapies are lacking. This is a 20-year follow-up study of a phase II trial that evaluated the activity and safety of docetaxel in combination with
-
In Reply to "Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer". Oncologist (IF 5.8) Pub Date : 2023-11-02 Luca F Valle,Nicholas G Nickols,Kosj Yamoah,Isla P Garraway,Kara N Maxwell,Julie A Lynch
-
Biomarker Testing Trends in Patients With Metastatic Colorectal Cancer Who Live in Rural Areas and Urban Clusters in the US. Oncologist (IF 5.8) Pub Date : 2023-11-02 Mark A Lewis,Lindsay Stansfield,John M Kelton,Christopher H Lieu
BACKGROUND There is a paucity of data on biomarker testing rates in rural populations with metastatic colorectal cancer (mCRC). To assess biomarker testing practices, oncologists in rural areas and urban clusters in the US were surveyed. MATERIALS AND METHODS A web-based survey was administered to oncologists spending ≥40% of their time practicing in rural areas or urban clusters and who had treated
-
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability. Oncologist (IF 5.8) Pub Date : 2023-11-02 Liliana Ascione,Edoardo Crimini,Dario Trapani,Antonio Marra,Carmen Criscitiello,Giuseppe Curigliano
Antibody-drug conjugates (ADCs) represent a cornerstone in the treatment of many cancers nowadays. ADCs fulfill their function by binding a target on tumor cell membrane to deliver a cytotoxic payload; in addition, those moieties capable of crossing cancer cell membranes can achieve near-by cells that do not express the target antigen, exerting the so-called "bystander" cytotoxic effect. The presence
-
A Pilot Study of F-18 Fluciclovine-PET/CT as a Diagnostic Tool for Bone Metastases in Patients With Castrate Resistant Prostate Adenocarcinoma and Correlative Analysis of Blood and Bone Molecular Testing (The FACT Study). Oncologist (IF 5.8) Pub Date : 2023-11-02 Hani M Babiker,Matthew D Kay,Carol Stuehm,Gregory Woodhead,Phillip H Kuo
BACKGROUND Suspicious F-18 fluciclovine PET/CT findings for osseous metastases from prostate cancer (PC) were targeted for core needle biopsy. We correlated the maximum standardized uptake value (SUVmax) of biopsied lesions, with biopsy results, other diagnostic outcomes, and blood and tissue molecular analysis (TMA). MATERIAL AND METHODS Patients with castrate resistant prostate cancer (CRPC) were
-
Racial Disparities and Molecular Insights in Translocation Renal Cell Carcinoma: Advancing Understanding and Treatment Approaches. Oncologist (IF 5.8) Pub Date : 2023-11-02 Patrick Campbell,Georges Gebrael,Neeraj Agarwal
-
Delayed Versus Immediate Start of Chemotherapy in Asymptomatic Patients With Advanced Cancer: A Meta-Analysis. Oncologist (IF 5.8) Pub Date : 2023-11-02 Simone Augustinus,Gajanan Thurairajah,Marc G Besselink,Hanneke W M van Laarhoven,Martijn G H van Oijen,Tara M Mackay,Johanna W Wilmink
BACKGROUND Due to increased use of imaging, advanced stages of cancer are increasingly being diagnosed in an early, asymptomatic phase. Traditionally, chemotherapy is started immediately in these patients. However, a strategy wherein chemotherapy is withheld until symptoms occur may be beneficial for patients in terms of quality of life (QOL). A systematic review regarding optimal timing of chemotherapy
-
Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer. Oncologist (IF 5.8) Pub Date : 2023-11-02 Oliver Sartor,Albert Jang,Elisa Ledet
-
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer. Oncologist (IF 5.8) Pub Date : 2023-11-02 Arielle Elkrief,Biagio Riccuiti,Joao V Alessi,Teng Fei,Hannah L Kalvin,Jacklynn V Egger,Hira Rizvi,Rohit Thummalapalli,Guiseppe Lamberti,Andrew Plodkowski,Matthew D Hellmann,Mark G Kris,Maria E Arcila,Marina K Baine,Charles M Rudin,Piro Lito,Marc Ladanyi,Adam J Schoenfeld,Gregory J Riely,Mark M Awad,Kathryn C Arbour
BACKGROUND Direct KRASG12C inhibitors are approved for patients with non-small cell lung cancers (NSCLC) in the second-line setting. The standard-of-care for initial treatment remains immune checkpoint inhibitors, commonly in combination with platinum-doublet chemotherapy (chemo-immunotherapy). Outcomes to chemo-immunotherapy in this subgroup have not been well described. Our goal was to define the
-
Opioid Risk Mitigation Practices of Interprofessional Oncology Personnel: Results From a Cross-Sectional Survey. Oncologist (IF 5.8) Pub Date : 2023-11-02 Gretchen A McNally,Eric M McLaughlin,Emily Ridgway-Limle,Robin Rosselet,Robert Baiocchi
BACKGROUND This study explored the risk mitigation practices of multidisciplinary oncology health-care personnel for the nonmedical use of opioids in people with cancer. METHODS An anonymous, cross-sectional descriptive survey was administered via email to eligible providers over 4 weeks at The Ohio State University's Arthur G. James Cancer Hospital. The survey asked about experiences and knowledge
-
Financial Toxicity: Unveiling the Burden of Cancer Care on Patients in Rwanda. Oncologist (IF 5.8) Pub Date : 2023-10-28 Fidel Rubagumya,Brooke Wilson,Achille Manirakiza,Emmanuel Mutabazi,Diane A Ndoli,Emmanuel Rudakemwa,Mary D Chamberlin,Wilma M Hopman,Christopher M Booth
INTRODUCTION Cancer is a major public health problem in Rwanda and other low- and middle-income countries (LMICs). While there have been some improvements in access to cancer treatment, the cost of care has increased, leading to financial toxicity and treatment barriers for many patients. This study explores the financial toxicity of cancer care in Rwanda. METHODS This prospective cross-sectional study
-
Three-Week Versus 4-Week Schedule of nab-Paclitaxel in Patients With Metastatic Breast Cancer: A Randomized Phase II Study. Oncologist (IF 5.8) Pub Date : 2023-10-26 Yaxin Liu,Guohong Song,Lijun Di,Hanfang Jiang,Ran Ran,Ruyan Zhang,Yan Zhang,Huiping Li
BACKGROUND This head-to-head study compared a 3-week versus 4-week schedule of nab-paclitaxel in patients with metastatic breast cancer (mBC). METHODS Patients with HER2-negative mBC were enrolled and randomly assigned (1:1) to receive nab-paclitaxel for a 3-week schedule (125 mg/m2 on days 1 and 8) or a 4-week schedule (same dose on days 1, 8, and 15) until disease progression or treatment intolerance
-
The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review. Oncologist (IF 5.8) Pub Date : 2023-10-25 Christina Vivelo,Karlyne M Reilly,Brigitte C Widemann,Mary Frances Wedekind,Corrie Painter,Allison F O'Neill,Sabine Mueller,Olivier Elemento,Andrea M Gross,Abby B Sandler
Rare cancers and other rare nonmalignant tumors comprise 25% of all cancer diagnoses and account for 25% of all cancer deaths. They are difficult to study due to many factors, including infrequent occurrence, lack of a universal infrastructure for data and/or tissue collection, and a paucity of disease models to test potential treatments. For each individual rare cancer, the limited number of diagnosed
-
Real-World Patient Experience of Pexidartinib for Tenosynovial Giant-Cell Tumor. Oncologist (IF 5.8) Pub Date : 2023-10-24 Feng Lin,Winghan Jacqueline Kwong,Irene Pan,Xin Ye,Dong Dai,William Tap
BACKGROUND Pexidartinib (Turalio) is the only systemic therapy approved by the FDA for the treatment of adult patients with symptomatic tenosynovial giant-cell tumor (TGCT) associated with severe morbidity or functional limitations, and not amenable to improvement with surgery. This study assessed patient-reported treatment experiences and symptom improvement among patients receiving pexidartinib.
-
Incidence Trends, Clinicopathologic Characteristics, and Overall Survival Prediction in Retinoblastoma Children: SEER Prognostic Nomogram Analysis. Oncologist (IF 5.8) Pub Date : 2023-10-24 Xiaohong Guo,Li Wang,Narasimha M Beeraka,Chunying Liu,Xiang Zhao,Runze Zhou,Huiming Yu,Ruitai Fan,Junqi Liu
BACKGROUND Retinoblastoma is the most common intraocular malignant tumor occurring among children, with an incidence rate of 1/15 000. This study built a joinpoint regression model to assess the incidence trend of retinoblastoma from 2004 to 2015 and constructed a nomogram to predict the overall survival (OS) in children. MATERIALS AND METHODS Patients less than 19 years diagnosed with retinoblastoma
-
Comparisons of Nonoral Immune-Related Adverse Events Among Patients With Cancer With Different Oral Toxicity Profiles. Oncologist (IF 5.8) Pub Date : 2023-10-24 Yuanming Xu,Natalie Wen,Robert I Haddad,Stephen T Sonis,Alessandro Villa
OBJECTIVES Immune-related adverse events (irAEs) are common. Oral irAEs tend to cluster in patients who experience concurrent toxicities. We aimed to characterize the frequency and trajectory of nonoral irAEs in patients who developed oral irAEs, assess their relationship with nonoral irAEs, and compare those characteristics with patients without oral irAEs. METHODS A retrospective chart review was
-
Presence, Subtypes, and Prognostic Significance of Tertiary Lymphoid Structures in Urothelial Carcinoma of the Bladder. Oncologist (IF 5.8) Pub Date : 2023-10-24 Guofeng Ma,Huiqing Jia,Guofang Zhang,Ye Liang,Xianning Dong,Guangming Fu,Xinsheng Wang,Haitao Niu
OBJECTIVE To evaluate the presence and subtypes of tertiary lymphatic structures (TLSs) in urothelial carcinoma of the bladder (UCB) and to analyze their associated clinicopathological characteristics and prognostic significance. METHODS The study enrolled 580 patients with surgically treated UCB, including 313 non-muscle invasive bladder cancer (NMIBC) and 267 muscle-invasive bladder cancer (MIBC)
-
Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study. Oncologist (IF 5.8) Pub Date : 2023-10-24 Jianwei Liu,Xiaodong Zhu,Yangxun Pan,Jianhong Zhong,Renan Jin,Xin Zheng,Wei Zhang,Kuan Hu,Jian Ma,Xiaoyi Shi,Hongzhi Liu,Xiaobo Yang,Da Xu,Chi Ma,Jiangming Chen,Dongxu Wang,Xiaojun Wang,Zhongchao Li,Lei Zhao,Leida Zhang,Tao Li,Fubao Liu,Guang Tan,Baocai Xing,Haitao Zhao,Yongyi Zeng,Shuijun Zhang,Lei Zhang,Ledu Zhou,Tianqiang Song,Wei Yang,Xiao Liang,Bangde Xiang,Li Xu,Huichuan Sun,Kui Wang
BACKGROUND The difference in the prognoses between treatment with surgical therapy and continuation of local-plus-systemic therapy following successful down-staging of intermediate-advanced hepatocellular carcinoma (HCC) remains unclear. METHODS Data of 405 patients with intermediate-advanced HCC treated at 30 hospitals across China from January 2017 to July 2022 were retrospectively reviewed. All
-
Challenging Rationality: Examining the Belief in Cure Among Patients With Advanced Incurable Cancers. Oncologist (IF 5.8) Pub Date : 2023-10-20 Carlos Eduardo Paiva,Bianca Sakamoto Ribeiro Paiva
-
A Rare Presentation of Aggressive Renal Cell Carcinoma and the Utility of Early Molecular Testing in Rapidly Progressing Malignancies: A Case Report. Oncologist (IF 5.8) Pub Date : 2023-10-16 Daniel E McLoughlin,Nicholas Chevalier,Edwin Choy,Gregory M Cote,Xin Gao,Dejan Juric,Kerry L Reynolds
In rapidly progressing cancers, appropriate selection of first-line therapy is essential in prolonging survival. Alongside immunohistochemistry (IHC), comprehensive genomics, including whole exome and transcriptome sequencing (WES/WTS), can improve diagnostic accuracy and guide therapeutic management. Here, we report a young patient with rapidly progressing malignancy and unexpected post-mortem results
-
-
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial. Oncologist (IF 5.8) Pub Date : 2023-10-09 Neal D Shore,Maha Hussain,Fred Saad,Karim Fizazi,Cora N Sternberg,David Crawford,Bertrand Tombal,Luke Nordquist,Michael Cookson,Frank Verholen,Jay Jhaveri,Shankar Srinivasan,Matthew R Smith
BACKGROUND In the ARASENS trial (NCT02799602), darolutamide in combination with androgen-deprivation therapy (ADT) and docetaxel significantly reduced the risk of death by 32.5% (HR, 0.68; 95% CI, 0.57-0.80; P < .0001) compared with placebo plus ADT with docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC). We present efficacy and safety of darolutamide versus placebo in
-
Screening, Diagnosis, and Initial Care of Asian and White Patients With Lung Cancer. Oncologist (IF 5.8) Pub Date : 2023-10-05 Xiao Hu,John W Melson,Stacey S Pan,Yana V Salei,Yu Cao
BACKGROUND Data on the care of Asian patients with lung cancer in the US are limited; however, lung cancer is the leading cause of cancer death in this population. METHODS Demographics, low-dose computed tomography (LDCT) screening, disease characteristics, and treatment history were compared between Asian and White patients newly diagnosed with lung cancer from 2014 to 2019 identified from Tufts Medical
-
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study. Oncologist (IF 5.8) Pub Date : 2023-10-05 Federica Pecci,Luca Cantini,Valeria Cognigni,Fabiana Perrone,Giulia Mazzaschi,Veronica Agostinelli,Giulia Mentrasti,Elda Favari,Michele Maffezzoli,Alessio Cortellini,Francesca Rossi,Rebecca Chiariotti,Francesco Maria Venanzi,Giuseppe Lo Russo,Giulia Galli,Claudia Proto,Monica Ganzinelli,Francesca Tronconi,Francesca Morgese,Carla Campolucci,Marco Moretti,Arianna Vignini,Marcello Tiseo,Roberta Minari
BACKGROUND Specific components of lipid profile seem to differently impact on immune activity against cancer and unraveling their prognostic role in patients with solid cancer treated with immune checkpoint inhibitors (ICIs) is needed. MATERIALS AND METHODS We retrospectively collected baseline clinicopathological characteristics including circulating lipid profile (total cholesterol [TC], triglycerides
-
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group. Oncologist (IF 5.8) Pub Date : 2023-10-03 Çağlar Ünal,Abdulmunir Azizy,Senem Karabulut,Didem Taştekin,Arif Akyıldız,Serkan Yaşar,Şuayib Yalçın,Eyüp Çoban,Türkkan Evrensel,Ziya Kalkan,Zeynep Oruç,Sümeyra Derin,Zeynep Hande Turna,Doğan Bayram,Fahriye Tuğba Köş,Mehmet Ali Nihat Şendur,Nadiye Sever,Özlem Ercelep,Mustafa Seyyar,Umut Kefeli,Kazım Uygun,Melike Özçelik,Sercan Ön,Ulus Ali Şanlı,Kübra Canaslan,İlkay Tuba Ünek,Kadriye Bir Yücel,Nuriye
INTRODUCTION This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs). METHODS We conducted a multicenter retrospective study analyzing the data of 308 patients with metastatic NETs treated with CAPTEM between 2010 and 2022 in 34 different hospitals across various regions
-
Can Precision Oncology Benefit Patients With Cancers of Unknown Primary? Oncologist (IF 5.8) Pub Date : 2023-10-03 Elie Rassy,Fabrice Andre
-
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both. Oncologist (IF 5.8) Pub Date : 2023-10-03 Marc P Bonaca,Javid J Moslehi,Jonathan A Ledermann,Elisabete Michelon,Caimiao Wei,Michael Moran,Bradley J Monk,Eric Pujade-Lauraine
In the phase III JAVELIN Ovarian 200 trial, 566 patients with platinum-resistant/refractory ovarian cancer were randomized 1:1:1 to receive avelumab alone, avelumab plus pegylated liposomal doxorubicin (PLD), or PLD alone. Cardiac monitoring was included for all patients. We report left ventricular ejection fraction (LVEF) data from the trial. Grade ≥3 cardiac adverse events (AEs) occurred in 4 (2
-
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay. Oncologist (IF 5.8) Pub Date : 2023-10-03 Hao-Kuen Lin,Thuy Can,Adriana Kahn,Cynthia A Flannery,Jess Hoag,Alekhya Akkunuri,Helen Bailey,Rick Baehner,Lajos Pusztai,Mariya Rozenblit
BACKGROUND HER2 immunohistochemistry (IHC) reproducibility is suboptimal for HER-low cases (IHC 1+ or 2+). METHODS The Yale cohort included 214 stages I-II estrogen receptor positive breast cancers with IHC scores 0, 1+, and 2+ and routine Oncotype DX Recurrence Score (RS) results. The Exact Sciences (ES) cohort included 9 57 624 patients who had an Oncotype DX RS assay that assigns HER2-negative,
-
The Evolving Landscape of Immune Checkpoint Inhibitors and Antibody Drug Conjugates in the Treatment of Early-Stage Breast Cancer. Oncologist (IF 5.8) Pub Date : 2023-10-03 Prarthna V Bhardwaj,Yara G Abdou
For decades, chemotherapy has been the mainstay of breast cancer treatment. Novel therapies are expanding the therapeutic options and altering the treatment algorithms to manage this disease. The use and approval of immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) represent a few areas of progress. These therapies initially gained attention in the metastatic setting but have
-
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program. Oncologist (IF 5.8) Pub Date : 2023-10-03 Fanny Le Du,Matthieu Carton,Thomas Bachelot,Mahasti Saghatchian,Barbara Pistilli,Etienne Brain,Delphine Loirat,Laurence Vanlemmens,Thomas Vermeulin,George Emile,Anthony Gonçalves,Mony Ung,Marie Robert,Anne Jaffre,Isabelle Desmoulins,Christelle Jouannaud,Lionel Uwer,Jean Marc Ferrero,Marie-Ange Mouret-Reynier,William Jacot,Michaël Chevrot,Suzette Delaloge,Véronique Diéras
BACKGROUND Although adjuvant cancer treatments increase cure rates, they may induce clonal selection and tumor resistance. Information still lacks as whether (neo)adjuvant anti-HER2 treatments impact the patterns of recurrence and outcomes of HER2-positive (HER2+) metastatic breast cancer (MBC). We aimed to assess this in the large multicenter ESME real-world database. PATIENTS AND METHODS We examined
-
Prognostic Risk Stratification and End-of-Life Care Outcomes in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors. Oncologist (IF 5.8) Pub Date : 2023-10-03 Robert N Grad,Seungyeon Jung,Fei Ye,Lili Sun,Douglas B Johnson,Rajiv Agarwal
INTRODUCTION The emergence of immune checkpoint inhibitors (ICIs) has improved survival outcomes in patients with metastatic melanoma, while potentially increasing the use of systemic therapy near the end of life (EOL). Yet, less is known on how to facilitate treatment decision making and identify patients who might benefit from early palliative care comanagement. MATERIALS AND METHODS We determined
-
Evaluating the Effectiveness of Mobile Health in Breast Cancer Care: A Systematic Review. Oncologist (IF 5.8) Pub Date : 2023-10-03 Madeleine Flaucher,Anastasiya Zakreuskaya,Michael Nissen,Alexander Mocker,Peter A Fasching,Matthias W Beckmann,Bjoern M Eskofier,Heike Leutheuser
Breast cancer is affecting millions of people worldwide. If not appropriately handled, the side effects of different modalities of cancer treatment can negatively impact patients' quality of life and cause treatment interruptions. In recent years, mobile health (mHealth) interventions have shown promising opportunities to support breast cancer care. Numerous studies implemented mobile health interventions
-
Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey. Oncologist (IF 5.8) Pub Date : 2023-10-03 Fatima Cardoso,Julie Rihani,Victoria Harmer,Nadia Harbeck,Ana Casas,Hope S Rugo,Peter A Fasching,Adam Moore,Joanna de Courcy,Purnima Pathak,Sina Haftchenary,Dawn Aubel,Eva Schumacher-Wulf
BACKGROUND Quality of life (QOL) is a critical factor in decision-making for advanced breast cancer (ABC). There is a need to improve how QOL and treatment-related side effects (SEs) that impact it are clinically assessed. We examined healthcare professionals' (HCPs') and patients' perspectives on the importance of QOL discussions and the impact of SEs on QOL in clinical settings. PATIENTS AND METHODS
-
Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer. Oncologist (IF 5.8) Pub Date : 2023-10-03 Hope S Rugo,Xianchen Liu,Benjamin Li,Lynn McRoy,Connie Chen,Rachel M Layman,Adam Brufsky
BACKGROUND Disparities in survival and clinical outcomes between African American and White patients with breast cancer (BC) are well documented, but African American patients have not been well represented in randomized clinical trials of CDK4/6 inhibitors. Real-world studies can provide evidence for effective treatment strategies for underreported patient populations. PATIENTS AND METHODS This retrospective
-
Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes. Oncologist (IF 5.8) Pub Date : 2023-10-03 Tanios S Bekaii-Saab,Krzysztof Lach,Ling-I Hsu,Muriel Siadak,Mike Stecher,James Ward,Rachel Beckerman,John H Strickler
BACKGROUND HER2 overexpression/amplification in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) may be associated with resistance to standard-of-care anti-EGFR therapies. Given the lack of comprehensive investigations into this association, we assessed the prognostic or predictive effect of HER2 amplification/overexpression on anti-EGFR treatment outcomes. METHODS A systematic